Per available comprehensive tumor next-generation sequencing (NGS) reports, done as part of SOC practices, we’ve looked at known predictive markers of ICIs response such as tumor mutational burden and POLE/POLD mutations. The gene discussed is POLD1; the disease is neoplasm.